Torsten J. Schulze

TL;DR: The data highlight a complex association between circulating inflammatory mediators, Mo‐MDSCs and the clinical outcome as well as suggest that their levels in patients with advanced melanoma are of important prognostic value allowing the identification of those with high risk of disease progression.

TL;DR: These findings validate the importance of the CCR5/CCR5 ligand axis not only for MDSC recruitment but also for further activation of their immunosuppressive functions in the tumor microenvironment, with potentially broad therapeutic implications, given existing clinically available inhibitors of this axis.

TL;DR: High-throughput exome- and/or deep-sequencing data revealed highly dynamic shaping of complex oligoclonal architectures, specifically upon treatment with lenalidomide and other drugs, substantiate a need for regular broad molecular monitoring to guide clinical treatment decisions in MDS.

TL;DR: The level of eosinophils is suggested as a novel predictive marker for melanoma patients who may benefit from this immunotherapy by highlighting additional mechanisms of ICI effects and suggesting that clinical responses to ICI treatment were associated with an eOSinophil accumulation in the peripheral blood.

TL;DR: It is demonstrated that Ig expression is a defining feature of monocytes and also macrophages in the tumor microenvironment and thus reveal an as yet unrecognized modus operandi of host defense in professional phagocytes.